Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of PRL-8-53 and Sunifiram — mechanism, side effects, legal status, and pricing.
PRL-8-53 is a non-peptide small-molecule aminoalkyl benzoic acid ester (methyl benzoate derivative), supplied as the hydrochloride salt. Originally characterized in 1974 animal studies as a spasmolytic and CNS-active agent, it has never been approved by any regulatory agency and is sold only as a research chemical. Exactly one published human trial exists—a 1978 double-blind study on verbal learning and retention—with no independent replication or modern safety data.
Sunifiram (DM-235) is a synthetic non-peptide piperazine derivative marketed online as an 'ampakine-like' cognitive enhancer. Despite common branding, primary research shows it acts indirectly via the glycine-binding site of the NMDA receptor to potentiate AMPA-receptor-mediated transmission, not as a direct AMPA agonist. No human clinical trials or toxicology studies have been conducted, and sunifiram is not approved for any human or veterinary use worldwide. It is sold on the gray market without regulatory vetting.
PRL-8-53
Sunifiram
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
PRL-8-53
Sunifiram
COA corpus from Disclosed Labs — independently tested batches only.
PRL-8-53
3
COAs
96.8%
Avg purity
2
Labs
Sunifiram
1
COAs
99.5%
Avg purity
1
Labs
Exactly one published human study was located: a 1978 double-blind trial (Hansl & Mead, <em>Psychopharmacology</em>, PMID 418433) using the serial anticipation method to test oral PRL-8-53 on verbal learning acquisition and retention, with follow-up on visual reaction time and motor control; the study reported statistically significant retention improvement (most P<0.01) and no significant reaction-time or motor effects, but sample size and exact dose are not stated in the available abstract. No further human trials were found, and no ClinicalTrials.gov entries exist. Preclinical work is limited to the 1974 Hansl paper (PMID 4824605) in dogs and rats, indexed for avoidance learning, conditioning, memory, and pharmacological interaction with apomorphine and methamphetamine, though full quantitative findings could not be verified because no abstract text is available.
No human data exist. In olfactory-bulbectomized mice given oral sunifiram 0.01–1.0 mg/kg daily for 7–12 days, spatial reference memory (Y-maze) and short-term recognition memory (novel object recognition) improved, and impaired hippocampal CA1 long-term potentiation was restored via NMDAR-glycine-site-dependent CaMKII/PKC signaling (blocked by gavestinel). In mouse hippocampal slices, sunifiram (1–1000 nM, peaking at 10 nM with a bell-shaped dose-response) potentiated CA1 LTP via the glycine-site/PKCα/CaMKII pathway. In passive-avoidance models, sunifiram reversed amnesia in mice and rats at doses roughly four orders of magnitude lower than piracetam. No toxicology studies or human clinical trials have been conducted as of 2016.
PRL-8-53 and Sunifiram are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs